ITGR — Integer Holdings Corporation

Integer Holdings Corporation (ITGR) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Sales: $440 million, up 0.5% year-over-year (1.3% organic growth).
• Adjusted EBITDA: $85 million, down 7% year-over-year.
• Adjusted Operating Income: Declined 14% with a margin of 13.9%, down 230 basis points.
• Adjusted Net Income: $41 million, down 10% year-over-year.
• Adjusted Earnings Per Share (EPS): $1.20, down 8% year-over-year.
• Cash Flow from Operations: $25 million, down $6 million from the prior year.
• Capital Expenditures (CapEx): $24 million, resulting in free cash flow of $1 million.
• Net Total Debt: $1.264 billion, with a leverage ratio of 3.2x trailing 4-quarter adjusted EBITDA.

2. Strategic Updates and Business Highlights:

• The company is undergoing a strategic review to explore options for maximizing shareholder value due to heightened interest in Integer.
• Focus remains on high-growth markets such as electrophysiology (EP), structural heart, neurovascular, and neuromodulation.
• The company has a robust product pipeline and plans to launch new products in all growth markets in the latter half of 2026 and in 2027.
• Management emphasized maintaining customer relationships and service quality while implementing cost reduction measures.

3. Forward Guidance and Outlook:

• 2026 Sales Outlook: Expected to be between $1.805 billion and $1.835 billion, reflecting a decline of 1% to 3% year-over-year.
• Organic Sales Growth: Anticipated to be flat to down 1%, with a headwind of 3% to 4% from three new products.
• Adjusted EBITDA: Expected to range from $375 million to $399 million, down 1% to 7% year-over-year.
• Adjusted EPS: Projected to be between $5.83 and $6.40, flat to down 9% year-over-year.
• Management expects a return to organic sales growth above market levels (200 basis points) in 2027.

4. Bad News, Challenges, or Points of Concern:

• The decline in adjusted operating income and margins is attributed to lower fixed cost absorption and recent customer forecast adjustments.
• The exit from the portable medical business and the impact of three new products are significant headwinds affecting overall sales.
• The electrophysiology market is experiencing normalization, leading to variability in customer forecasts and order patterns, which may impact revenue in the short term.
• The company is cautious about potential risks and has implemented further risk adjustments across its portfolio.

5. Notable Q&A Insights:

• Management clarified that the recent forecast reductions in the EP segment are not linked to the previously discussed new products but reflect a normalization of the market.
• There is confidence that the EP market will continue to grow in the mid- to high teens despite recent adjustments.
• The strategic review was initiated due to increased interest in Integer, with no specific timeline for completion.
• Management remains committed to maintaining investments in product development despite current headwinds, emphasizing the importance of long-term growth strategies.
• The company is closely monitoring inflation and supply chain dynamics, indicating that current inflationary pressures are manageable and not a significant concern.

This summary encapsulates the key points from Integer Holdings Corporation's Q1 2026 earnings call, highlighting the company's financial performance, strategic direction, and outlook amidst current challenges.